Pharmacodynamics of fosfomycin against ESBL- and/or carbapenemase-producing Enterobacteriaceae | Zendy

Fiona Fransen | Zendy; Kelly Hermans | Zendy; Maria J. Melchers | Zendy; Claudia C M Lagarde | Zendy; Joseph Meletiadis | Zendy; Johan W. Mouton | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

Pharmacodynamics of fosfomycin against ESBL- and/or carbapenemase-producing Enterobacteriaceae

Author(s) -

Fiona Fransen,

Kelly Hermans,

Maria J. Melchers,

Claudia C M Lagarde,

Joseph Meletiadis,

Johan W. Mouton

Publication year - 2017

Publication title -

journal of antimicrobial chemotherapy

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 2.124

H-Index - 194

eISSN - 1460-2091

pISSN - 0305-7453

DOI - 10.1093/jac/dkx328

Subject(s) - fosfomycin , pharmacodynamics , microbiology and biotechnology , antibiotics , biology , antibiotic resistance , enterobacteriaceae , population , escherichia coli , drug resistance , pharmacology , medicine , pharmacokinetics , biochemistry , environmental health , gene

The increase in antibiotic resistance in Gram-negative bacteria and the limited therapeutic options due to the shortage of new antibiotics have increased the interest of the 'old' antibiotic fosfomycin in the treatment of infections. However, there are contradictory reports on the pharmacodynamics of and emergence of resistance to fosfomycin.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research